ARTICLE | Targets & Mechanisms

miR-21 joins the oncogene ranks

August 26, 2010 7:00 AM UTC

Yale University researchers have reported that microRNA-21 is an oncogene that drives the development-and maintenance-of hematological malignancies in mice.1 The team now plans to antagonize the molecule to treat blood cancers and, potentially, solid tumors.

Previous tissue profiling studies have found that multiple tumor types abnormally overexpress miR-21, including hematological malignancies,2,3glioblastomas4 and colorectal, lung, breast and pancreatic cancers.5 The open question was if miR-21 overexpression merely correlated with disease or if it was a true oncogene capable of triggering cancer and driving disease progression...